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Background: We aimed to investigate whether MIR31 is an oncogene in human endometrial cancer and identify
the target molecules associated with the malignant phenotype.
Methods: We investigated the growth potentials of MIR31-overexpressing HEC-50B cells in vitro and in vivo. In order
to identify the target molecule of MIR31, a luciferase reporter assay was performed, and the corresponding
downstream signaling pathway was examined using immunohistochemistry of human endometrial cancer tissues.
We also investigated the MIR31 expression in 34 patients according to the postoperative risk of recurrence.
Results: The overexpression of MIR31 significantly promoted anchorage-independent growth in vitro and significantly
increased the tumor forming potential in vivo. MIR31 significantly suppressed the luciferase activity of mRNA combined
with the LATS2 3’-UTR and consequently promoted the translocation of YAP1, a key molecule in the Hippo pathway,
into the nucleus. Meanwhile, the nuclear localization of YAP1 increased the transcription of CCND1. Furthermore, the
expression levels of MIR31 were significantly increased (10.7-fold) in the patients (n = 27) with a high risk of recurrence
compared to that observed in the low-risk patients (n = 7), and this higher expression correlated with a poor survival.
Conclusions: MIR31 functions as an oncogene in endometrial cancer by repressing the Hippo pathway. MIR31 is a
potential new molecular marker for predicting the risk of recurrence and prognosis of endometrial cancer.
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Endometrial cancer (EC) is the most common malig-
nancy of the female reproductive tract, the annual inci-
dence of which has been estimated to be 10–20 per
100,000 women [1]. Current therapy for EC includes
surgery with adjuvant radiation or chemotherapy [2].
The risk of postoperative recurrence is determined based
on several factors, such as the surgical stage [3], differ-
entiation [4], lymph node metastasis and lymphovascular
space invasion [5]. The 5-year survival rate for FIGO
stage I lesions without grade 3 tumor differentiation,
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unless otherwise stated.adenosquamous histology exceeds 90% [6]. However, the
5-year survival rate of patients with stage III and IV dis-
ease is dramatically decreased, ranging from 42% [7] to
79% [8]. EC can be divided into two major categories
based on clinicopathologic and molecular genetic fea-
tures. For example, low-grade carcinomas with PTEN
mutations associated with endometrial hyperplasia and
estrogenic stimulation, including mucinous or low-grade
endometrioid tumors with squamous differentiation, are
called type I carcinomas. In contrast, high-grade carcin-
omas with p53 mutations, such as serous carcinomas
and clear cell carcinomas, are referred to as type II cancers
[9]. It is important to identify new molecular mechanisms
underlying the process of endometrial carcinogenesis and
discover molecular targets and novel drugs for improving
survival.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.molecular-cancer.com/content/13/1/97microRNAs (MIRs) are endogenous non-coding RNAs
of 18 to 25 nucleotides in length that play important
roles in regulating the gene expression. The mature
forms of MIRs silence the gene expression by binding to
the 3’-untranslated region (UTR) of target mRNAs and
initiate the translational repression and/or cleavage of
cognate mRNAs [10]. MIRs have frequently been impli-
cated in carcinogenesis [11-14]. In the setting of EC,
MIR152 [15], MIR194 [16], MIR34b [17], MIR204 [18],
MIR145 [19] and MIR129-2 [20] have been reported to
be tumor suppressor genes, and MIR125b [21] has been
reported to be an oncogene (oncomir). Furthermore,
MIR31 has been reported to be an oncomir in various
human cancers, including colorectal [22], esophageal
[23], lung [24], oral [25] and head and neck [26] cancer,
and a tumor suppressor gene in breast [27] and gastric
[28] cancers and malignant mesothelioma [29]. How-
ever, little is known about the biological functions of
MIR31 in EC.
The Hippo pathway is crucial in regulating the size of
organs, and its dysregulation contributes to tumorigen-
esis [30]. Recently, it was reported that deregulation of
the Hippo pathway occurs at a high frequency in a
broad range of human cancers, including lung [24],
hepatocellular [31], colon [32] and prostate cancer [33],
and is often correlated with a poor patient prognosis.
LATS2 represents a core component in the kinase cas-
cade of the mammalian Hippo pathway. Interestingly, it
has been reported that the Hippo pathway is required
for anoikis and that the LATS2 expression levels are
significantly downregulated in patients with metastatic
prostate cancer [33].
In this study, we aimed to investigate whether MIR31
is an oncomir in human EC and identify the direct target
associated with the malignant phenotype of EC.
Results
MIR31 is correlated with enhanced colony formation of
EC cell lines
In order to investigate whether the MIR31 expression is
correlated with the tumorigenesis of EC, we performed
colony formation assays. We confirmed the MIR31 ex-
pression in three EC cell-lines, HEC-50B, HEC-1A and
HEC-108, using qRT-PCR and found that the MIR31
levels were lowest in the HEC-108 cells, followed by
HEC-1A and HEC-50B cells (Additional file 1: Figure S1,
Lanes 1, 2 and 3). The colony number was increased in
the same order as the MIR31 expression under two differ-
ent serum concentrations (Additional file 2: Figure S2).
The overexpression of MIR31 enhances tumorigenesis
in vitro and in vivo
We established HEC-50B cells overexpressing MIR31
by introducing precursor-MIR31 using lentivirus vectorsbecause the MIR31 expression level of HEC-50B was
modest among the several adenocarcinoma cell lines ana-
lyzed (Additional file 1: Figure S1) and lentivirus vectors
can be efficiently transfected into this cell line (HEC-50B
mock and MIR31). The presence of a mature-MIR31
expression was confirmed using qRT-PCR (Figure 1a).
Although MIR31 overexpression did not affect in vitro
cell proliferation under the standard culture conditions
(data not shown), it significantly promoted colony forma-
tion under serum starvation (Figure 1b). Additionally,
an MIR31-specific inhibitor significantly restrained colony
formation (Additional file 3: Figure S3). The MIR31-
mediated tumorigenic effects were confirmed in an in vivo
model. A significant increase in tumor weight was
observed in the HEC-50B cells with MIR31 overexpres-
sion compared with that noted in the controls in the
nude mice subcutaneous tumor model (Figure 1c).
These findings demonstrate that MIR31 induces a more
aggressive phenotype of EC.MIR31 reduces the protein levels of LATS2 by inhibiting
translation
In order to elucidate the mechanisms by which MIR31
promotes tumorigenesis, in silico prediction models were
employed to identify the target mRNAs of MIR31 [10].
Among several candidates, we focused on LATS2 be-
cause it is a known tumor suppressor gene that has
been previously reported to be a direct target of MIR31
[24,34]. One potential binding site for MIR31 was found
in the 3’-UTR region of LATS2 mRNA (Figure 2a).
To confirm that LATS2 is a target of MIR31 in HEC-
50B cells, the protein levels of LATS2 were analyzed in
HEC-50B cells overexpressing MIR31. We found that
LATS2 was downregulated in the MIR31-overexpressing
cells, whereas LATS2 was increased by the MIR31-
specific inhibitor compared with that observed in the
control cells in a Western blot analysis (Figure 2b). We
next performed a luciferase reporter assay to assess
whether MIR31 inhibits the translation of LATS2. The
detection of a normalized luciferase activity revealed that
MIR31 significantly suppressed the activity of luciferase
combined with wild-type LATS2 3’-UTR in the HEC-
50B MIR31 cells, whereas no differences were observed
following treatment with the control luciferase and
LATS2 3’-UTR possessing a mutation in the putative
MIR31-binding site (Figure 2c). As no significant differ-
ences in the LATS2 mRNA levels were observed be-
tween the HEC-50B control and MIR31-overexpressing
cells (Additional file 4: Figure S4), MIR31 does not ap-
pear to degrade LATS2 mRNA. These results suggest
that MIR31 directly binds to LATS2 mRNA and regu-
lates the LATS2 protein expression via translational
inhibition.
Figure 1 The overexpression of MIR31 enhanced tumorigenesis in vitro and in vivo. (a) Establishment of HEC-50B-expressing MIR31 cells.
The results of the qRT-PCR analysis of the expression levels of MIR31 are shown in the bar graph. *p < 0.05, unpaired two-tailed Student’s t-test.
The experiments were performed in triplicate. (b) Colony formation assay with 1% FBS. Representative stained colonies are displayed in the left
panel. *p < 0.05, unpaired two-tailed Student’s t-test. The experiments were performed in triplicate. (c) Subcutaneous tumors in the seven nude
mice are displayed in the left panel. The weights of tumors are shown in the right bar graph. *p < 0.05, paired two-tailed Student’s t-test.
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HEC-50B cells
In order to investigate whether the downregulation of
LATS2 is responsible for the enhanced colony-forming
ability of HEC-50B cells, the expression of LATS2 was
suppressed by two different short hairpin RNAs (shRNAs)
(Figure 2d bottom), and the treated cells were evaluated
for tumorigenesis using a colony formation assay under
low serum concentrations. After 12 weeks of severe star-
vation (incubation with 1% fetal bovine serum (FBS)),
increased colony formation was clearly observed in the
cells with LATS2 suppression, whereas treatment with
nonspecific shRNA did not affect colony formation
(Figure 2d top). We observed the same findings follow-
ing treatment with 5% FBS for four weeks (Additional
file 5: Figure S5). These results suggest that the suppres-
sion of the LATS2 expression induced by MIR31 con-
tributes to enhanced tumorigenesis.
MIR31 promotes the transcription of cyclin D1 (CCND1)
via dysregulation of the Hippo signaling pathway
The Hippo tumor suppressor pathway regulates several
cellular functions, including proliferation, survival and
metastasis. In the Hippo pathway, the transcriptional co-
activator YAP1 translocates into the nucleus, where it pro-
motes the transcription of several target genes associatedwith proliferation and anti-apoptosis. LATS2 is the key
molecule in this pathway and promotes the phosphoryl-
ation of YAP1. The phosphorylation of YAP1 by LATS2
inhibits the translocation of YAP1 into the nucleus and
thus prevents the transcription of YAP1 target genes [30].
Therefore, when LATS2 is suppressed by MIR31, it is
expected that the translocation of YAP1 into the nucleus
would be promoted. In order to confirm the YAP1 trans-
location, we performed immunofluorescence. The cells
successfully transfected with control or precursor MIR31
vectors expressed Green Fluorescent Proteins (Figure 3a
top), and YAP1 was stained with Cy5 (Figure 3a bottom).
As expected, we found that the nuclear translocation of
YAP1 frequently occurred in the MIR31-overexpressing
cells compared with that observed in the control cells
(Figure 3b). In addition, YAP phosphorylation was either
not different or slightly increased in the HEC-50B MIR31
cells compared with that observed in the HEC-50B cells
(not significant, Additional file 6: Figure S6). These results
suggest that the translocation of YAP1 into the nucleus is
the most important effect of MIR31.
Because we hypothesized that nuclear YAP1 pro-
motes the transcription of several anti-apoptosis and
pro-proliferation genes, we analyzed the expression
levels of several proteins, including CCND1, RAS, XIAP,
cyclin E1, MYC, KIT, JNK, AKT, FAS, FADD, FASLG and
Figure 2 MIR31 regulates the LATS2 expression by inhibiting translation. (a) The potential binding site for MIR31 in 3’UTR of LATS2 mRNA.
(b) The expression level of LATS2 in the mock and MIR31-overexpressing cells (top). The LATS2 expression was increased by the MIR31-specific
inhibitor (bottom). The results of immunoblotting for LATS2 and α-tubulin are shown. (c) The luciferase activity after transfection of the indicated
3’-UTR-driven reporter constructs. Reporter plasmids containing no oligonucleotides as a Control, the wild-type 3’UTR region of LATS2 as a Wild
type and the mutant 3’UTR region as a Mutant. *p < 0.05, unpaired two-tailed Student’s t-test. (d) Colony formation assay (bar graph) and
immunoblotting for LATS2 and α-tubulin following shRNA transfection (bottom panel). *p < 0.05, unpaired two-tailed Student’s t-test. All experiments
were performed in triplicate.
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cells using immunoblotting (Additional file 7: Figure S7).
We found the MIR31 overexpression to be associated
with increased CCND1, RAS and XIAP expression
levels (Figure 3c, Additional file 8: Figure S8a top) and
they also decreased in the anti-MIR31-oligonucleotide-
induced cells (Figure 3c, Additional file 8: Figure S8a
bottom). Because these results strongly suggest that
nuclear YAP1, which is increased by the MIR31 expres-
sion, promotes the transcription of these targets, we
performed luciferase reporter assays in order to investigate
the influence of MIR31 on the transcription of CCND1,
RAS and XIAP. The detection of a normalized luciferase
activity revealed that the MIR31 expression significantly
increased the activity of luciferase driven by the CCND1,
RAS and XIAP promoters compared with that observed
in the control cells (Figure 3d Line 1–2, Additional file 8:Figure S8b). In addition, we focused on the CCND1 ex-
pression and investigated the influence of nuclear YAP1
overexpression on the CCND1 expression. HEC-50B cells
were transfected with a YAP1 expression vector, the results
of which confirmed that nuclear YAP1 was overexpressed
on immunofluorescence (Additional file 9: Figure S9).
As expected, YAP suppression by anti-YAP siRNA sig-
nificantly decreased the activity of luciferase driven by
the CCND1 promotor, and the expression of CCND1
was increased by YAP1 overexpression (Figure 3d, Lines
2–3, Figure 3e).
We also found a correlation between the MIR31, LATS2
and CCND1 expression in vivo (mouse 7 in Figure 1c). The
LATS2 expression was increased in the control cell tumors
compared with that observed in the MIR31-expressing
tumor cells, and the CCND1 levels were increased in the
tumors formed from MIR31-expressing cells (Figure 3f).
Figure 3 MIR31 promotes the translocation of YAP1 into the nucleus and promotes the transcription of CCND1. (a) Representative cells
of immunofluorescence for GFP and YAP1, x600. The nuclei are indicated by white arrows. *The translocation of YAP1 into the nucleus was not
observed in the cells unsuccessfully transfected with pre-MIR31. The cells were cultured under standard conditions with 5% fetal bovine serum.
(b) Ratio of nuclear YAP1 staining. *p < 0.05, unpaired two-tailed Student’s t-test. (c) The CCND1 levels were increased by MIR31 overexpression
and the CCND1 levels were decreased by the MIR31-specific inhibitor on immunoblotting for CCND1 and α-tubulin. The ratio of CCND1/α-tubulin
is shown in the bar graph. (d) The CCND1 levels were increased by YAP1 overexpression. Immunoblotting for YAP1, CCND1 and α-tubulin.
(e) The luciferase activity after transfection of the reporter constructs containing the LATS2 promotor region normalized to the GAPDH promotor
region (top). Immunoblotting for YAP and α-tubulin following siRNA transfection (bottom). Mock and MIR31 cells were transfected with non-targeting
siRNA. *p < 0.05, unpaired two-tailed Student’s t-test. (f) Correlation between the MIR31 expression and results of the immunohistochemical analysis of
LATS2 and CCND1 in vivo. Representative results are shown in micrographs, x100. All experiments were performed in triplicate.
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expression in EC
We compared the MIR31 expression quantified by qRT-
PCR and the immunohistochemical expression of
LATS2 and CCND1 in 34 EC patients who underwent
surgery as their initial treatment (Table 1, Lane 1). When
we divided the 34 patients into two groups according to
the MIR31 expression (MIR31/RNU44 = 15), the MIR31
expression levels were found to be low in the LATS2-
positive (73%) and CCND1-negative (27%) tumors and
high in the LATS2-negative (25%) and CCND1-positive
(75%) tumors. (Figure 4a; Two representative cases are
shown in Figure 4b). The MIR31 expression was lowest
in the LATS2-positive and CCND1-negative groups and
highest in the LATS2-negative and CCND1-positive
groups (Figure 4c).
The MIR31 expression is increased in high-risk human
endometrial cancers
We defined low-risk patients as those who satisfied all of
the following criteria: pT1a, pN0, M0, grade1 or 2 with-
out lymphovascular space invasion (Table 1, Lanes 2 and3). We found that the expression of MIR31 was signifi-
cantly increased in the high-risk patients (Figure 4d).
All patients with recurrent disease were classified as
high-risk patients. Since most tumors in the recurrent
disease patients were of grade 2 (Table 1, Lane 4), we fo-
cused on the prognosis of the 13 patients with grade 2
tumors (Additional file 10: Table S1). As expected, the
progression-free survival was significantly worse among
the patients with high MIR31 tumors (> = 0.8) than
among those with low MIR31 tumors (<0.8) (Figure 5).
These results suggest that MIR31 is related to the ag-
gressiveness of EC.
Discussion
In this study, we demonstrated that MIR31 functions as
an oncomir in EC. MIR31 is an oncomir in several hu-
man cancers and a tumor suppressor gene in others. We
speculate that MIR31 has a specific function in each
type of malignancy, and several mechanisms, including
methylation-dependent silencing [35] and local deletion
[29], may explain its different roles in different tumor
types. However, little is known about the MIR31 status
Table 1 Clinical features of human endometrial cancer
Total Low-risk High-risk Recurrence
n (%) 34 (100) 7 (21) 27 (79) 7 (21)
Age, mean
(range)
59 (38–78) 58 (38–75) 60 (45–78) 56 (45–67)
FIGO stage,
n (%)
I 15 (44) 7 (100) 8 (30) 1 (14)
II 3 (9) 0 (0) 3 (11) 1 (14)
III 14 (41) 0 (0) 14 (52) 3 (43)
IV 2 (6) 0 (0) 2 (7) 2 (29)
Grade, n (%)
1 15 (44) 5 (71) 10 (37) 0 (0)
2 13 (38) 2 (29) 11 (41) 6 (86)




+ 10 (29) 0 (0) 10 (37) 2 (29)
- 24 (71) 7 (100) 17 (63) 5 (71)
MIR31, mean 18.40 2.05 21.90 9.15
(range) (0.15 - 284.06) (0.33 - 5.98) (0.15 - 284.06) (0.70 - 27.77)
Mitamura et al. Molecular Cancer 2014, 13:97 Page 6 of 11
http://www.molecular-cancer.com/content/13/1/97in patients with EC. In previous studies that reported
MIR31 to be an oncomir, MIR31 was found to regulate
RAS p21 GTPase Activating Protein 1 (RASA1) [22] and
RhoBTB1 [36] in colorectal cancer, LATS2 and PP2A
regulatory subunit B alpha isoform (PPP2R2A) [24] in
lung cancer and factor-inhibiting hypoxia-inducible
factor (FIH) [26] in head and neck carcinomas. It is
plausible that MIR31 represses the expression of tumor
suppressor genes, such as LATS2, to act as an oncomir
and indirectly promotes the transcription of genes re-
lated to cell cycle control and tumorigenesis (Figure 6).
We herein demonstrated that the Hippo pathway is in-
volved in EC tumorigenesis and correlates with a poor
patient prognosis. Although no significant relationships
were observed between the immunohistochemical ex-
pression of LATS2 and clinical risk factors, including
lymph node metastasis, cervical invasion or lymphovas-
cular space invasion, such relationships deserve further
investigation in a larger patient cohort. It is reasonable to
postulate that the Hippo pathway regulates the CCND1
expression via YAP1 translocation into the nucleus in EC,
as the cyclin family is known to be a major target of the
Hippo pathway [37-39]. The overexpression of CCND1
may not be an independent factor causing tissue over-
growth, since it is suggested that the overexpression of all
known yorkie targets fails to mimic the effect of yorkie
itself in driving tissue growth in drosophila [40]. As
MIR31 tends to block the cell apoptosis induced byultraviolet treatment in HEC-50B cells (data not shown),
we speculate that other transcriptional targets of YAP1
associated with apoptosis, such as XIAP, may be coor-
dinately regulated with CCND1. The Hippo pathway is
known to be related to the p53 activity, for example,
LATS2 tumor suppressor augments p53-mediated apop-
tosis by promoting the nuclear proapoptotic function of
ASPP1 [41,42]. On the other hand, a p53 mutation is
found in some patients with aggressive histologic subtypes
of endometrial cancer [43]. Our findings suggested the
existence of a possible connection between MIR31 and
p53 mutation in EC which thus induces the aggressiveness
of EC. Additionally, the connection between MIR31 and
the p53 mutation could therefore explain the reason why
MIR31 either promotes or suppresses different cancers.
As mentioned above, recommendations for postope-
rative adjuvant therapy for EC are based on the risk
assessment of recurrence for each individual patient. In
this study, we divided 34 EC patients into two groups
according to the criteria generally used to determine
whether postoperative adjuvant therapy is required and
found a strong correlation between the MIR31 expres-
sion and these clinical risk factors. These results suggest
that MIR31 is potentially a new molecular marker for
distinguishing the risk of recurrence combined with
histological findings. However, the small sample size of
the present study limits the robustness of our findings,
and further investigation in a larger patient cohort is
necessary.
Conclusions
In conclusion, we herein demonstrated that MIR31 pro-
motes EC tumorigenesis. MIR31 indirectly promotes the
translocation of YAP1 into the nucleus by repressing the
tumor suppressor gene LATS2.
Methods
Human endometrial tumor tissues
Tumor specimens were obtained from patients with EC
treated at Hokkaido University Hospital under institu-
tional review board approval (registration ID: 011–0157).
Informed consent was obtained from each subject.
Patients treated at Hokkaido University Hospital between
2006 and 2012 were eligible for inclusion. All samples
were obtained at the initial surgery. RNA was extracted
using the RecoverAll™ Total nucleic Acid Isolation Kit
(Ambion, Austin, TX, USA) from formalin-fixed, paraffin-
embedded tissues. We set the samples on the slide glass
and microscopically recognized the malignantly trans-
formed epithelial lesion, then cored out the epithelial
lesion. MIR31 was detected using quantitative real-time
PCR (qRT-PCR). All experiments were performed three
times, and ratio of the mean MIR31 level relative to the
endogenous control RNU44 level was calculated.
Figure 4 Correlation between the MIR31 expression and the immunohistochemical detection of LATS2 and CCND1 in human EC cells.
(a) Proportion of patients with positive staining for LATS2 and CCND1 classified into the MIR31 > =15 and MIR31 < 15 groups. *p < 0.05, Chi-square test.
(b) The MIR31 expression assessed using qRT-PCR with RNU44 as the endogenous control (top) and representative micrographs, x100. (c) The MIR31
expression levels in all patients classified according to staining for LATS2 and CCND1 are shown in the scatter diagram. The horizontal solid lines
indicate the mean. (d) The expression levels of MIR31 in the human EC cells were analyzed using qRT-PCR. The horizontal lines demonstrate the mean.
*p < 0.05, Mann-Whitney's U-test.
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Total RNA was extracted using TRIzol Reagent (Invitro-
gen, Carlsbad, CA, USA). The MIR31 and RNU44 levels
were quantified using qRT-PCR with the TaqMan® Micro-
RNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA) and TaqMan® MicroRNA Assays
(Applied Biosystems) according to the manufacturer's
instructions. We assessed the RNA expression accord-
ing to relative quantification using the 2-ΔΔCt method
[44] to determine the fold change in the expression.
Cell lines
The human EC cell lines HEC-50B, HEC-1-A and HEC-
108 were obtained from RIKEN BioResource Center
(Tsukuba, Japan) and maintained in Dulbecco's Modified
Eagle’s Medium (DMEM) with 10% FBS, 2 mM L-glu-
tamine and 100 U/ml of penicillin and streptomycin in a
6-cm dish. SK-OV-3 and OVCAR-3 were obtained from
the ATCC (Manassas, VA, USA) and maintained in Mc-
Coy’s 5a Medium with 10% FBS, 2 mM L-glutamine and
100 U/ml of penicillin and streptomycin and in RoswellPark Memorial Institute medium 1640 with 20% FBS,
0.01 mg/ml of bovine insulin, 2 mM L-glutamine and
100 U/ml of penicillin and streptomycin.Overexpression of MIR31
Precursor-MIR31 was transfected into HEC-50B using
the BLOCK-iT™ Lentiviral miR RNAi Expression System
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s protocol, as previously described [45]. After transfec-
tion, we performed blasticidin selection at a concentration
of 2.5 μg/ml for 10 days.Colony formation assay
A total of 1.0 × 105 cells were seeded in a layer of 0.4%
noble agar/DMEM/1% FBS/0.5 μg/ml of puromycin or
0.4% noble agar/DMEM/5% FBS over a layer of 0.5% bacto
agar/DMEM/1% or 5% FBS in a 6-cm dish. The colonies
were stained using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide solution (Sigma-Aldrich, St. Louis,
MO, USA) and counted.
Figure 5 Prognosis of patients classified into the high and low MIR31 groups. Kaplan–Meier curves depicting the progression-free survival
(PFS). *p < 0.05, log-rank test.
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All experiments were conducted in accordance with
guidelines authorized by the Animal Research Commit-
tee of Hokkaido University. Six-week-old BALB/c nude
mice (Clea, Tokyo, Japan) were injected subcutaneously
into their flanks with 2 x 107 HEC-50B mock or HEC-
50B MIR31 cells bilaterally in 200 μl of normal culture
medium. All mice were sacrificed on day 28, and the
tumor weight was measured.
Immunoblotting
SDS–PAGE and immunoblotting were carried out as
described elsewhere [45]. Briefly, filters were incubatedFigure 6 Schematic drawing of the Hippo pathway in human EC.with rabbit polyclonal antibodies against LATS2, mouse
monoclonal antibodies against α-tubulin (1:1,000 dilu-
tion, Abcam, Cambridge, UK), rabbit polyclonal antibodies
against CCND1 (1:500 dilution, Santa Cruz Biotechnology,
Dallas, TX, USA), rabbit polyclonal antibodies against
YAP1 and phospho-YAP (Ser127) (1:1,000 dilution, Cell
Signaling Technology, Danvers, MA, USA), mouse mo-
noclonal antibodies against RAS (1:1,000 dilution, BD
Biosciences, San Jose, CA, USA) and rabbit polyclonal
antibodies against XIAP (1:100 dilution, Abnova, Taipei
City, Taiwan).
Luciferase reporter assay
To investigate the translation of LATS2, luciferase re-
porter assay was carried out as described elsewhere [45].
The wild-type (NM_014572) or mutant LATS2 3’-UTR
sequence was inserted downstream of the firefly luci-
ferase reporter gene, which was controlled by the SV40
enhancer for expression in mammalian cells, whereas no
oligonucleotides were inserted in the control vector
(Genecopoeia, Rockville, MD, USA). Renilla luciferase
was used as a tracking indicator for successful transfec-
tion. In order to investigate the transcription of CCND1,
HRAS, KRAS and XIAP, luciferase reporter constructs
for the promoters of these molecules and a positive control
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were obtained (SwitchGear Genomics, Menlo Park, CA,
USA). The luciferase activity was measured using Light-
Switch Assay Reagent (SwitchGear Genomics) according to
the manufacturer's instructions. Briefly, 1.0 to 1.5 × 104
cells were seeded in white 96–well plates on day 1 and
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FuGENE HD (Promega). The luciferase activity was mea-
sured using assay reagent 48 hours after transfection.
RNA interference for LATS2 and YAP1
Two shRNA lentiviruses against LATS2 (Sigma-Aldrich)
and non-targeting shRNA (Sigma-Aldrich) were trans-
fected into HEC-50B cells in 48-well plates according to
the manufacturer's instructions. The multiplicity of in-
fection (MOI, number of transducing lentiviral particles
per cell) was 5. We performed puromycin selection at a
concentration of 0.5 μg/ml for 10 days. siRNAs against
YAP and non-targeting siRNA (Santa Cruz Biotechnol-
ogy) were transfected using HiPerFect transfection re-
agent (Qiagen, Tokyo, Japan) in 12-well plates, and the
cells were harvested after 48 hours.
Reverse transcription-PCR
Reverse transcription-PCR was carried out as described
elsewhere [45]. The primers used for the expression ana-
lysis were as follows: pre- MIR31 - forward, 5'-GGAGAG-
GAGGCAAGATGCTG-3'; pre- MIR31 - reverse, '-GGA
AAGATGGCAATATGTTG-3': GAPDH - forward, 5'-C
TCATGACCACAGTCCATGC-3': GAPDH - reverse, 5'-
TTACTCCTTGGAGGCCATGT-3': LATS2 - forward, 5'-
TAGAGCAGAGGGCGCGGAAG -3': LATS2 - reverse,
5'- CCAACACTCCACCAGTCACAGA-3'.
Immunofluorescence
Cells were grown on 35-mm glass-based dishes (Asahi
Glass, Tokyo, Japan), fixed with 3% paraformaldehyde
and permeabilized with 0.1% Triton X-100/PBS before
blocking with 1% BSA. The cells were incubated with
rabbit polyclonal antibodies against YAP1 (1:500 dilu-
tion, Cell Signaling Technology) and secondary anti-
bodies, including goat antibodies to rabbit coupled to
Alexa 594 (1:250 dilution, Invitrogen). All samples were
examined using laser-scanning confocal microscopy
(Fluoview™, Olympus, Tokyo, Japan).
MIR inhibitor
A total of 200 nM of miRIDIAN microRNA Hairpin
Inhibitor and its negative control (Thermo Scientific
Dharmacon, Lafayette, CO, USA) were employed to
transiently inhibit MIR31 and transfected 48 hours
prior to seeding with Oligofectamine (Invitrogen).
Overexpression of Yes-associated protein 1 (YAP1)
The human YAP1 expression vector, p2xFLAG-YAP1
and negative control were kindly provided by Dr. Sudol
[46]. HEC-50B cells at 80% confluence in 6-well plates
were transfected with 4 μg of YAP1 vector using FuGENE
HD (Promega).Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded tissues were used
to detect the LATS2 and CCND1 expression. The sec-
tions were incubated with anti-LATS2 rabbit poly-
clonal antibodies (Abcam, Cambridge, UK) at 1:300
dilution and anti-CCND1 rabbit monoclonal anti-
bodies (Dako, Glostrup, Denmark) at 1:50 dilution. A
semi-quantitative scoring system was used to evaluate
the intensity of staining: low (proportion: 0 to 50%, in-
tensity: no staining to weak) and high (proportion:
more than 50%, intensity: intermediate to strong).Statistical analysis
The data are presented as the mean ± SEM. The un-
paired two-tailed Student’s t-test, Mann-Whitney's U-
test and Chi-square test were used for comparisons,
with a p value of < 0.05 considered to be significant (*).Additional files
Additional file 1: Figure S1. qRT-PCR analysis of the MIR31 expression
in five adenocarcinoma cell lines of the female genital tract.
Additional file 2: Figure S2. Colony formation assay. *p < 0.05,
unpaired two-tailed Student’s t-test compared with HEC-108.
Additional file 3: Figure S3. Colony formation assay, four weeks.
*p < 0.05, unpaired two-tailed Student’s t-test.
Additional file 4: Figure S4. Detection of LATS2 and GAPDH mRNA
using RT–PCR.
Additional file 5: Figure S5. Representative results of the colony
formation assays with 5% FBS for four weeks.
Additional file 6: Figure S6. MIR31 is not involved in YAP
phosphorylation. Immunoblotting for phospho-YAP and α-tubulin.
Additional file 7: Figure S7. Immunoblotting for putative targets of YAP1.
Additional file 8: Figure S8. (a) The expression levels of RAS and XIAP
in the mock and MIR31-overexpressing cells (top). The RAS and XIAP
levels were decreased by the MIR31-specific inhibitor (bottom). Results of
immunoblotting for RAS, XIAP and α-tubulin. (b) The luciferase activity
after transfection of the reporter constructs containing the HRAS, KRAS
and XIAP promotor region normalized to the GAPDH promotor region.
*p < 0.05, unpaired two-tailed Student’s t-test.
Additional file 9: Figure S9. Representative immunofluorescence
analysis of YAP1, x600.
Additional file 10: Table S1. Correlation between the MIR31 expression
and risk of postoperative recurrence in the patients with grade 2 tumors.
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